NASDAQ:FIXX

Homology Medicines Competitors

$6.81
-0.22 (-3.13 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$6.56
Now: $6.81
$7.03
50-Day Range
$7.03
MA: $9.48
$11.26
52-Week Range
$6.76
Now: $6.81
$17.34
Volume910,017 shs
Average Volume538,432 shs
Market Capitalization$343.82 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.24

Competitors

Homology Medicines (NASDAQ:FIXX) Vs. KROS, CMPS, STTK, RPTX, DVAX, and OCUL

Should you be buying FIXX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Homology Medicines, including Keros Therapeutics (KROS), COMPASS Pathways (CMPS), Shattuck Labs (STTK), Repare Therapeutics (RPTX), Dynavax Technologies (DVAX), and Ocular Therapeutix (OCUL).

Keros Therapeutics (NASDAQ:KROS) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Keros Therapeutics and Homology Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros TherapeuticsN/AN/AN/AN/AN/A
Homology Medicines$1.67 million205.88$-103,920,000.00($2.47)-2.76

Keros Therapeutics has higher earnings, but lower revenue than Homology Medicines.

Profitability

This table compares Keros Therapeutics and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Keros TherapeuticsN/AN/AN/A
Homology Medicines-5,386.00%-57.92%-45.33%

Insider & Institutional Ownership

58.4% of Keros Therapeutics shares are held by institutional investors. Comparatively, 75.2% of Homology Medicines shares are held by institutional investors. 33.4% of Homology Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Keros Therapeutics and Homology Medicines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Keros Therapeutics00403.00
Homology Medicines01502.83

Keros Therapeutics currently has a consensus price target of $78.00, indicating a potential upside of 37.64%. Homology Medicines has a consensus price target of $27.8571, indicating a potential upside of 309.06%. Given Homology Medicines' higher probable upside, analysts plainly believe Homology Medicines is more favorable than Keros Therapeutics.

Summary

Homology Medicines beats Keros Therapeutics on 5 of the 9 factors compared between the two stocks.

COMPASS Pathways (NASDAQ:CMPS) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares COMPASS Pathways and Homology Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
Homology Medicines$1.67 million205.88$-103,920,000.00($2.47)-2.76

COMPASS Pathways has higher earnings, but lower revenue than Homology Medicines.

Profitability

This table compares COMPASS Pathways and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
Homology Medicines-5,386.00%-57.92%-45.33%

Insider & Institutional Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 75.2% of Homology Medicines shares are held by institutional investors. 33.4% of Homology Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for COMPASS Pathways and Homology Medicines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00603.00
Homology Medicines01502.83

COMPASS Pathways currently has a consensus price target of $70.75, indicating a potential upside of 105.97%. Homology Medicines has a consensus price target of $27.8571, indicating a potential upside of 309.06%. Given Homology Medicines' higher probable upside, analysts plainly believe Homology Medicines is more favorable than COMPASS Pathways.

Summary

COMPASS Pathways beats Homology Medicines on 6 of the 10 factors compared between the two stocks.

Shattuck Labs (NASDAQ:STTK) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Analyst Recommendations

This is a summary of current recommendations and price targets for Shattuck Labs and Homology Medicines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shattuck Labs00603.00
Homology Medicines01502.83

Shattuck Labs currently has a consensus price target of $45.60, indicating a potential upside of 51.95%. Homology Medicines has a consensus price target of $27.8571, indicating a potential upside of 309.06%. Given Homology Medicines' higher probable upside, analysts plainly believe Homology Medicines is more favorable than Shattuck Labs.

Profitability

This table compares Shattuck Labs and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shattuck LabsN/AN/AN/A
Homology Medicines-5,386.00%-57.92%-45.33%

Earnings and Valuation

This table compares Shattuck Labs and Homology Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shattuck LabsN/AN/AN/AN/AN/A
Homology Medicines$1.67 million205.88$-103,920,000.00($2.47)-2.76

Shattuck Labs has higher earnings, but lower revenue than Homology Medicines.

Insider & Institutional Ownership

75.2% of Homology Medicines shares are held by institutional investors. 33.4% of Homology Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Shattuck Labs beats Homology Medicines on 5 of the 9 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 75.2% of Homology Medicines shares are owned by institutional investors. 33.4% of Homology Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repare Therapeutics and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
Homology Medicines-5,386.00%-57.92%-45.33%

Earnings & Valuation

This table compares Repare Therapeutics and Homology Medicines' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
Homology Medicines$1.67 million205.88$-103,920,000.00($2.47)-2.76

Repare Therapeutics has higher earnings, but lower revenue than Homology Medicines.

Analyst Ratings

This is a breakdown of current recommendations for Repare Therapeutics and Homology Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
Homology Medicines01502.83

Repare Therapeutics presently has a consensus target price of $39.40, indicating a potential upside of 16.98%. Homology Medicines has a consensus target price of $27.8571, indicating a potential upside of 309.06%. Given Homology Medicines' higher probable upside, analysts plainly believe Homology Medicines is more favorable than Repare Therapeutics.

Summary

Repare Therapeutics beats Homology Medicines on 5 of the 9 factors compared between the two stocks.

Homology Medicines (NASDAQ:FIXX) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Homology Medicines and Dynavax Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Homology Medicines01502.83
Dynavax Technologies00403.00

Homology Medicines currently has a consensus price target of $27.8571, suggesting a potential upside of 309.06%. Dynavax Technologies has a consensus price target of $16.3333, suggesting a potential upside of 48.62%. Given Homology Medicines' higher possible upside, equities analysts plainly believe Homology Medicines is more favorable than Dynavax Technologies.

Earnings & Valuation

This table compares Homology Medicines and Dynavax Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Homology Medicines$1.67 million205.88$-103,920,000.00($2.47)-2.76
Dynavax Technologies$35.22 million35.34$-152,600,000.00($1.87)-5.88

Homology Medicines has higher earnings, but lower revenue than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Homology Medicines and Dynavax Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Homology Medicines-5,386.00%-57.92%-45.33%
Dynavax Technologies-256.92%-193.85%-23.45%

Volatility & Risk

Homology Medicines has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Institutional and Insider Ownership

75.2% of Homology Medicines shares are held by institutional investors. Comparatively, 80.0% of Dynavax Technologies shares are held by institutional investors. 33.4% of Homology Medicines shares are held by company insiders. Comparatively, 13.3% of Dynavax Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ocular Therapeutix (NASDAQ:OCUL) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 75.2% of Homology Medicines shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by company insiders. Comparatively, 33.4% of Homology Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ocular Therapeutix and Homology Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million285.76$-86,370,000.00($2.01)-7.91
Homology Medicines$1.67 million205.88$-103,920,000.00($2.47)-2.76

Ocular Therapeutix has higher revenue and earnings than Homology Medicines. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ocular Therapeutix and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Homology Medicines-5,386.00%-57.92%-45.33%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ocular Therapeutix and Homology Medicines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Homology Medicines01502.83

Ocular Therapeutix presently has a consensus price target of $24.80, suggesting a potential upside of 56.07%. Homology Medicines has a consensus price target of $27.8571, suggesting a potential upside of 309.06%. Given Homology Medicines' higher possible upside, analysts plainly believe Homology Medicines is more favorable than Ocular Therapeutix.

Volatility & Risk

Ocular Therapeutix has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Summary

Ocular Therapeutix beats Homology Medicines on 8 of the 15 factors compared between the two stocks.


Homology Medicines Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
Gap Down
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Gap Down
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
News Coverage
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
News Coverage
Gap Down
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-0.1%$858.83 millionN/A-10.37Analyst Report
News Coverage
Merus logo
MRUS
Merus
1.6$22.52-1.7%$858.62 million$31.13 million-7.34Analyst Report
Ardelyx logo
ARDX
Ardelyx
1.6$8.69-0.3%$857.53 million$5.28 million-8.60High Trading Volume
Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.51-0.3%$839.98 million$23.96 million-16.12Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.82-5.4%$838.42 millionN/A-22.98
Epizyme logo
EPZM
Epizyme
1.8$8.10-1.6%$824.46 million$23.80 million-3.63
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.30-0.3%$820.59 million$322.36 million123.57
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.27-0.8%$819.20 million$296.70 million47.49Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$14.73-5.6%$787.79 millionN/A0.00Increase in Short Interest
Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33-2.7%$782.70 millionN/A0.00Increase in Short Interest
Gap Down
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02-0.1%$755.02 million$148.36 million-7.02Analyst Revision
News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.71-0.2%$728.84 million$40.89 million-3.35
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.63-1.9%$702.93 million$6.83 million-20.24
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.